This past year has been tough for Regeneron Pharmaceuticals. Regeneron (REGN) today released positive data from a late stage study of its closely watched cholesterol-lowering drug Praluent. The biotech giant announced that adding the injectable drug to existing treatment reduced so-called “bad cholesterol” by 50% in patients with an inherited form of high cholesterol, and reduced the need for an expensive procedure that removes the dangerous fats from a patient’s blood.
Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) said today that trials of their cholesterol drug Praulent met targets.
- Zacks•2 days ago
Regeneron Pharmaceuticals (REGN) and Sanofi presented positive phase III data on Praluent in patients who underwent LDL apheresis therapy.
Regeneron Pharmaceuticals, Inc. (REGN)
NasdaqGS - NasdaqGS Delayed Price. Currency in USD
|Bid||378.01 x 200|
|Ask||410.00 x 100|
|Day's Range||394.42 - 402.36|
|52wk Range||329.09 - 592.59|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||61.66|
|Avg Vol (3m)||822,492|
|Dividend & Yield||N/A (N/A)|